2017
DOI: 10.1080/23312025.2017.1288335
|View full text |Cite
|
Sign up to set email alerts
|

The effect of ascorbic acid on bone cancer cells in vitro

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
7
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 30 publications
4
7
0
Order By: Relevance
“…Considering the single antioxidants tested, hydroxycinnamic acids seem not to have antiproliferative activity on this cell line ( Figure 1), independently from the concentration (1-500 µM) or the length time of the treatment (24 h or 48 h), in agreement also with Martini et al [21]. The same considerations can be made for ascorbic acid, which does not induce any change in HT29 cells viability in the tested concentrations range (Figure 1), according to what observed by Fernandes et al in 2017 on bone cancer cells cell line [22].…”
Section: Discussionsupporting
confidence: 89%
“…Considering the single antioxidants tested, hydroxycinnamic acids seem not to have antiproliferative activity on this cell line ( Figure 1), independently from the concentration (1-500 µM) or the length time of the treatment (24 h or 48 h), in agreement also with Martini et al [21]. The same considerations can be made for ascorbic acid, which does not induce any change in HT29 cells viability in the tested concentrations range (Figure 1), according to what observed by Fernandes et al in 2017 on bone cancer cells cell line [22].…”
Section: Discussionsupporting
confidence: 89%
“…Similarly, the clonogenic survival of both cell lines after treatment with 75 pmole/cell (7.5 mM) of P-AscH − was significantly decreased compared to normal canine fibroblasts (Figure 5B). This is similar to human OSA in vitro studies, which showed a dose-dependent decrease in cell growth following exposure to P-AscH − (range of doses up to 1 mM) and a sparing of normal control cells; the most significant growth effects were found at the 1 mM concentration (50, 51). Similar findings have been confirmed for a variety of human tumors (7).…”
Section: Discussionsupporting
confidence: 85%
“…Some methods to reduce the high-failure rate would be to target known signaling pathways [ 22 ], especially pathways that are proven to generate results. By formulating newer drugs to act on these known pathways or targets, it significantly reduces the risk of failure [ 22 , 23 , 24 ]. This transfers the risk to start-up companies that are financed by either bigger pharmaceutical companies or IPOs and is a well-known strategy in other industries that can be applied to drug innovations.…”
Section: Role Of Systems Biology In Drug Discovery and Developmentmentioning
confidence: 99%